Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9926 |
High Similarity |
NPD6190 |
Approved |
0.8312 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.831 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.8276 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8037 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.8012 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7939 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.784 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.784 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.784 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7786 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7785 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7771 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7744 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7736 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7722 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7712 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7673 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7671 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7658 |
Intermediate Similarity |
NPD1934 |
Approved |
0.764 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7632 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7632 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7628 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7613 |
Intermediate Similarity |
NPD1512 |
Approved |
0.761 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7605 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7603 |
Intermediate Similarity |
NPD3764 |
Approved |
0.759 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7578 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.756 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7554 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7547 |
Intermediate Similarity |
NPD37 |
Approved |
0.7534 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7532 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.753 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7516 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7516 |
Intermediate Similarity |
NPD4965 |
Approved |
0.75 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD943 |
Approved |
0.75 |
Intermediate Similarity |
NPD9268 |
Approved |
0.75 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7485 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7484 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7483 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7452 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7442 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.744 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.744 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7438 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7425 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7412 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7397 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7394 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7391 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7383 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7383 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7372 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7371 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7365 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7362 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7358 |
Intermediate Similarity |
NPD3455 |
Phase 2 |
0.7349 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7342 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7333 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7303 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7257 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7226 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7215 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7095 |
Approved |
0.716 |
Intermediate Similarity |
NPD6386 |
Approved |
0.716 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7143 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7126 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7107 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7107 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7099 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7086 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7078 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7078 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7076 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7073 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7066 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7055 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7051 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7047 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD7966 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD9570 |
Approved |
0.703 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7007 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6535 |
Approved |
0.7 |
Intermediate Similarity |
NPD6534 |
Approved |
0.6993 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6993 |
Remote Similarity |
NPD447 |
Suspended |
0.6993 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6987 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6987 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6973 |
Remote Similarity |
NPD7435 |
Discontinued |
0.697 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6962 |
Remote Similarity |
NPD3750 |
Approved |
0.6954 |
Remote Similarity |
NPD7039 |
Approved |
0.6954 |
Remote Similarity |
NPD6559 |
Discontinued |
0.6954 |
Remote Similarity |
NPD7240 |
Approved |
0.6954 |
Remote Similarity |
NPD7038 |
Approved |
0.6943 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6941 |
Remote Similarity |
NPD5242 |
Approved |
0.6939 |
Remote Similarity |
NPD1608 |
Approved |
0.6928 |
Remote Similarity |
NPD826 |
Approved |
0.6928 |
Remote Similarity |
NPD825 |
Approved |
0.6928 |
Remote Similarity |
NPD4060 |
Phase 1 |
0.6923 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6906 |
Remote Similarity |
NPD3022 |
Approved |
0.6906 |
Remote Similarity |
NPD3021 |
Approved |
0.6902 |
Remote Similarity |
NPD6781 |
Approved |
0.6902 |
Remote Similarity |
NPD6778 |
Approved |
0.6902 |
Remote Similarity |
NPD6782 |
Approved |
0.6902 |
Remote Similarity |
NPD6780 |
Approved |
0.6902 |
Remote Similarity |
NPD6777 |
Approved |
0.6902 |
Remote Similarity |
NPD6776 |
Approved |
0.6902 |
Remote Similarity |
NPD6779 |
Approved |
0.6901 |
Remote Similarity |
NPD2629 |
Approved |
0.6894 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6885 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6885 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD8313 |
Approved |
0.6875 |
Remote Similarity |
NPD8312 |
Approved |
0.6871 |
Remote Similarity |
NPD1535 |
Discovery |
0.6863 |
Remote Similarity |
NPD6663 |
Approved |
0.6855 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6846 |
Remote Similarity |
NPD3225 |
Approved |
0.6845 |
Remote Similarity |
NPD8319 |
Approved |
0.6845 |
Remote Similarity |
NPD3749 |
Approved |
0.6845 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6832 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6829 |
Remote Similarity |
NPD3226 |
Approved |
0.6826 |
Remote Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.6824 |
Remote Similarity |
NPD1481 |
Phase 2 |
0.6821 |
Remote Similarity |
NPD5736 |
Approved |
0.6818 |
Remote Similarity |
NPD1240 |
Approved |
0.6815 |
Remote Similarity |
NPD5408 |
Approved |
0.6815 |
Remote Similarity |
NPD5405 |
Approved |
0.6815 |
Remote Similarity |
NPD5404 |
Approved |
0.6815 |
Remote Similarity |
NPD2796 |
Approved |
0.6815 |
Remote Similarity |
NPD5406 |
Approved |
0.6813 |
Remote Similarity |
NPD3887 |
Approved |
0.6813 |
Remote Similarity |
NPD2354 |
Approved |
0.6805 |
Remote Similarity |
NPD919 |
Approved |
0.6802 |
Remote Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.6795 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.679 |
Remote Similarity |
NPD3146 |
Approved |
0.679 |
Remote Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.679 |
Remote Similarity |
NPD2532 |
Approved |
0.679 |
Remote Similarity |
NPD2534 |
Approved |
0.679 |
Remote Similarity |
NPD2533 |
Approved |
0.6786 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6774 |
Remote Similarity |
NPD555 |
Phase 2 |
0.6772 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6754 |
Remote Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.6754 |
Remote Similarity |
NPD7874 |
Approved |
0.6752 |
Remote Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.675 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6748 |
Remote Similarity |
NPD6273 |
Approved |
0.6744 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6742 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6736 |
Remote Similarity |
NPD4198 |
Discontinued |
0.6735 |
Remote Similarity |
NPD17 |
Approved |
0.6731 |
Remote Similarity |
NPD6653 |
Approved |
0.6731 |
Remote Similarity |
NPD1607 |
Approved |
0.673 |
Remote Similarity |
NPD5958 |
Discontinued |
0.673 |
Remote Similarity |
NPD4534 |
Discontinued |
0.6727 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6727 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6725 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6725 |
Remote Similarity |
NPD1247 |
Approved |
0.6712 |
Remote Similarity |
NPD1894 |
Discontinued |
0.6711 |
Remote Similarity |
NPD2861 |
Phase 2 |
0.6709 |
Remote Similarity |
NPD2438 |
Suspended |
0.6702 |
Remote Similarity |
NPD7698 |
Approved |
0.6702 |
Remote Similarity |
NPD7697 |
Approved |
0.6702 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.669 |
Remote Similarity |
NPD9493 |
Approved |
0.669 |
Remote Similarity |
NPD228 |
Approved |
0.6689 |
Remote Similarity |
NPD1470 |
Approved |
0.6689 |
Remote Similarity |
NPD1203 |
Approved |
0.6689 |
Remote Similarity |
NPD2797 |
Approved |
0.6688 |
Remote Similarity |
NPD3268 |
Approved |
0.6687 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6686 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6685 |
Remote Similarity |
NPD8360 |
Approved |
0.6685 |
Remote Similarity |
NPD8361 |
Approved |
0.6667
|
Remote Similarity |
NPD2982 |
Phase 2 |